Efepime 1 gm/vial IM/IV Injection
Dosage : IM/IV Injection
Strength : 1 gm/vial
Generic : Cefepime Hydrochloride
Pack Size : 1 Pack = NA
Manufacturer : Ziska Pharmaceuticals Ltd.
- 100% āĻāϏāϞ āĻ āĻŽāĻžāύāϏāĻŽā§āĻĒāύā§āύ āĻāώā§āϧ â āĻāĻĒāύāĻžāϰ āϏā§āĻŦāĻžāϏā§āĻĨā§āϝā§āϰ āĻāύā§āϝ āĻāĻŽāĻžāĻĻā§āϰ āĻĒā§āϰāϤāĻŋāĻļā§āϰā§āϤāĻŋāĨ¤
- ⧝⧝⧝+ āĻāĻžāĻāĻžāϰ āĻā§āύāĻžāĻāĻžāĻāĻž āĻāϰā§āύ āĻāĻŦāĻ āĻĢā§āϰāĻŋ āĻšā§āĻŽ āĻĄā§āϞāĻŋāĻāĻžāϰāĻŋ āĻāĻĒāĻā§āĻ āĻāϰā§āύ!
- āύāĻŋāϰā§āĻŦāĻžāĻāĻŋāϤ āĻāϞāĻžāĻāĻžāϝāĻŧ āύāĻŋāϝāĻŧāĻŽāĻŋāϤ āĻĄā§āϞāĻŋāĻāĻžāϰāĻŋ āĻāĻžāϰā§āĻ āĻŽāĻžāϤā§āϰ ⧍ā§Ģ āĻāĻžāĻāĻžāĨ¤
- āĻ āϰā§āĻĄāĻžāϰā§āϰ āĻĒāϰ āĻĄā§āϞāĻŋāĻāĻžāϰāĻŋ āϏāĻŽāϝāĻŧ ā§§-ā§Ēā§Ž āĻāĻŖā§āĻāĻžāĨ¤
- āĻāώāϧ āĻāĻĒāϞāĻā§āϝ āύāĻž āĻĨāĻžāĻāϞ⧠āĻĄā§āϞāĻŋāĻāĻžāϰāĻŋ āĻŦāĻŋāϞāĻŽā§āĻŦāĻŋāϤ āĻšāϤ⧠āĻĒāĻžāϰ⧠āĻŦāĻž āĻ āϰā§āĻĄāĻžāϰ āĻŦāĻžāϤāĻŋāϞ āĻšāϤ⧠āĻĒāĻžāϰā§āĨ¤
- āĻāĻžāϰāĻŋāĻāϰāĻŋ āϤā§āϰā§āĻāĻŋāϰ āĻāĻžāϰāĻŖā§ āĻĒāĻŖā§āϝā§āϰ āĻŽā§āϞā§āϝ āĻ āϏāĻā§āĻāϤāĻŋāĻĒā§āϰā§āĻŖ āĻšāϞā§, āĻāϰā§āϤā§āĻĒāĻā§āώ āĻ āϰā§āĻĄāĻžāϰ āĻŦāĻžāϤāĻŋāϞā§āϰ āĻ āϧāĻŋāĻāĻžāϰ āϏāĻāϰāĻā§āώāĻŖ āĻāϰā§āĨ¤
Description
- Moderate to Severe Pneumonia due to S. pneumoniae, *P. aeruginosa, K. pneumoniae, or Enterobacter species: 1-2 gm IV 12 hourly for 10 days.
- Empiric therapy for febrile neutropenic patients: 2 gm IV 8 hourly for 7** days.
- Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis, due to E. coli, K. pneumoniae, or P. mirabilis*: 0.5-1 gm IV/IM*** 12 hourly for 7-10 days.
- Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis, due to E. coli or K. pneumoniae*: 2 gm IV 12 hourly for 10 days.
- Moderate to Severe Uncomplicated Skin and Skin Structure Infections due to S. aureus or S. pyogenes: 2 gm IV 12 hourly for 10 days.
- Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by E. coli, viridans group streptococci, P. aeruginosa, K. pneumoniae, Enterobacter species, or B. fragilis: 2 gm IV 12 hourly for 7-10 days.
Note:
*including cases associated with concurrent bacteremia.
**or until resolution of neutropenia. In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re evaluated frequently.
*** IM route of administration is indicated only for mild to moderate, uncomplicated or complicated UTls due to E. coli when the IM route is considered to be a more appropriate route of drug administration.
Reviews
There are no reviews yet.